Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBIT (2020 - 2025)

Historic EBIT for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to -$6.3 million.

  • Biofrontera's EBIT fell 2657.26% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 902.24%. This contributed to the annual value of -$17.2 million for FY2024, which is 2410.81% up from last year.
  • Latest data reveals that Biofrontera reported EBIT of -$6.3 million as of Q3 2025, which was down 2657.26% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's EBIT registered a high of -$1.7 million during Q4 2024, and its lowest value of -$16.1 million during Q3 2021.
  • Over the past 5 years, Biofrontera's median EBIT value was -$5.0 million (recorded in 2024), while the average stood at -$5.2 million.
  • In the last 5 years, Biofrontera's EBIT plummeted by 58707.34% in 2021 and then skyrocketed by 7740.45% in 2022.
  • Biofrontera's EBIT (Quarter) stood at -$1.9 million in 2021, then crashed by 196.86% to -$5.6 million in 2022, then skyrocketed by 30.75% to -$3.9 million in 2023, then soared by 55.71% to -$1.7 million in 2024, then plummeted by 266.71% to -$6.3 million in 2025.
  • Its EBIT stands at -$6.3 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$4.5 million for Q1 2025.